2024 Revenues ($USD) : $11.02B

Vertex Pharmaceuticals Incorporated posted full-year 2024 product revenue of $11.02 billion, a solid 12% increase. The company invested $3.63 billion into R&D during the year and finished 2024 sitting on $11.2 billion in cash and marketable securities. Looking ahead, Vertex is guiding for revenue between $11.75 billion and $12.0 billion for 2025.

On the commercial and regulatory front, Vertex highlighted a couple of recent wins. It snagged U.S. FDA approval for ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a new once-daily CFTR modulator combo for CF patients six and older. It also got the green light for JOURNAVX, which it's touting as a novel non-opioid option for moderate-to-severe acute pain. Meanwhile, the global rollout of CASGEVY, its CRISPR gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia, continued, with Vertex reporting over 50 treatment centers up and running worldwide by the end of 2024.

The pipeline is humming along too. Vertex pointed to four key assets moving through pivotal trials with updates expected: Suzetrigine (VX-548) targeting peripheral neuropathic pain, Povetacicept (VX-147) for IgA nephropathy, Inaxaplin (also VX-147, but a different compound) aiming at APOL1-mediated kidney disease, and Zimislecel (VX-880) for type 1 diabetes.

There’s also a shuffle happening in the C-suite effective July 1, 2025. Stuart Arbuckle, the current Chief Operating Officer, is planning to retire. Charlie Wagner, the CFO, will pick up the COO duties in addition to his finance role. And Duncan McKechnie, who heads North America Commercial, will step up to become Chief Commercial Officer. The company’s message remains focused on diversifying its revenue streams, pushing its multi-therapeutic pipeline forward, and expanding its footprint geographically.